Cargando…
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
OBJECTIVES: Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%. The present study (RAPIDS-2, f...
Autores principales: | Matucci-Cerinic, Marco, Denton, Christopher P, Furst, Daniel E, Mayes, Maureen D, Hsu, Vivien M, Carpentier, Patrick, Wigley, Fredrick M, Black, Carol M, Fessler, Barri J, Merkel, Peter A, Pope, Janet E, Sweiss, Nadera J, Doyle, Mittie K, Hellmich, Bernhard, Medsger, Thomas A, Morganti, Adele, Kramer, Fabrice, Korn, Joseph H, Seibold, James R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002766/ https://www.ncbi.nlm.nih.gov/pubmed/20805294 http://dx.doi.org/10.1136/ard.2010.130658 |
Ejemplares similares
-
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension
por: Iannone, F, et al.
Publicado: (2008) -
Clinical trials in systemic sclerosis: lessons learned and outcomes
por: Matucci-Cerinic, Marco, et al.
Publicado: (2007) -
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
por: Denton, C P, et al.
Publicado: (2008) -
Bosentan monohydrate
por: Kaur, Manpreet, et al.
Publicado: (2012) -
Studies on the Vitrified and Cryomilled Bosentan
por: Minecka, Aldona, et al.
Publicado: (2021)